{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T05:05:33Z","timestamp":1780549533660,"version":"3.54.1"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journalofsubstanceabusetreatment.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Substance Abuse Treatment"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.jsat.2021.108686","type":"journal-article","created":{"date-parts":[[2021,12,15]],"date-time":"2021-12-15T17:45:30Z","timestamp":1639590330000},"page":"108686","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"special_numbering":"C","title":["Examining differences in retention on medication for opioid use disorder: An analysis of Ohio Medicaid data"],"prefix":"10.1016","volume":"136","author":[{"given":"Pengyue","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krystel","family":"Tossone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Ashmead","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tina","family":"Bickert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emelie","family":"Bailey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan J.","family":"Doogan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aimee","family":"Mack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Schuyler","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea E.","family":"Bonny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jsat.2021.108686_bb0010","unstructured":"American Society of Addiction Medicine, n.d.American Society of Addiction Medicine. Medicaid coverage of medications for the treatment of opioid use disorder. American Society of Addiction Medicine. Retrieved from https:\/\/www.asam.org\/advocacy\/aaam\/smr\/ohio."},{"issue":"2","key":"10.1016\/j.jsat.2021.108686_bb0015","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1177\/0306624X18789832","article-title":"Evaluation of treatment and other factors that Lead to drug court success, substance use reduction, and mental health symptomatology reduction over time","volume":"63","author":"Baughman","year":"2019","journal-title":"International Journal of Offender Therapy and Comparative Criminology"},{"issue":"8","key":"10.1016\/j.jsat.2021.108686_bb9000","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1176\/appi.ajp.2016.16070792","article-title":"The Role of Behavioral Interventions in Buprenorphine Maintenance Treatment: A Review","volume":"174","author":"Carroll","year":"2017","journal-title":"American Journal of Psychiatry"},{"key":"10.1016\/j.jsat.2021.108686_bb0020","author":"Centers for Disease Control and Prevention (CDC)"},{"issue":"2","key":"10.1016\/j.jsat.2021.108686_bb9010","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","article-title":"Regression Models and Life-Tables","volume":"34","author":"Cox","year":"1972","journal-title":"Journal of the Royal Statistical Society Series B-Statistical Methodology"},{"issue":"1\u20133","key":"10.1016\/j.jsat.2021.108686_bb0025","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.drugalcdep.2011.06.023","article-title":"Employment-based reinforcement of adherence to an FDA approved extended release formulation of naltrexone in opioid-dependent adults: A randomized controlled trial","volume":"120","author":"DeFulio","year":"2012","journal-title":"Drug and Alcohol Dependence"},{"issue":"1","key":"10.1016\/j.jsat.2021.108686_bb0030","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1037\/a0030743","article-title":"Employment-based reinforcement of adherence to oral naltrexone treatment in unemployed injection drug users","volume":"21","author":"Dunn","year":"2013","journal-title":"Experimental and Clinical Psychopharmacology"},{"issue":"6","key":"10.1016\/j.jsat.2021.108686_bb0035","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1002\/cpt.857","article-title":"When and how can real world data analyses substitute for randomized controlled Trials?","volume":"102","author":"Franklin","year":"2017","journal-title":"Clinical Pharmacology & Therapeutics"},{"issue":"2","key":"10.1016\/j.jsat.2021.108686_bb0040","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.pnpbp.2010.12.002","article-title":"Supervised daily consumption, contingent take-home incentive and non-contingent take-home in methadone maintenance","volume":"35","author":"Gerra","year":"2011","journal-title":"Progress in Neuro-Psychopharmacology & Biological Psychiatry"},{"issue":"6","key":"10.1016\/j.jsat.2021.108686_bb0045","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1007\/s10461-012-0393-9","article-title":"A randomized controlled trial to evaluate the relative efficacy of the addition of a psycho-social intervention to standard-of-care services in reducing attrition and improving attendance among first-time users of methadone maintenance treatment in China","volume":"17","author":"Gu","year":"2013","journal-title":"AIDS and Behavior"},{"issue":"5","key":"10.1016\/j.jsat.2021.108686_bb0050","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1097\/ADM.0000000000000166","article-title":"American Society of Addiction Medicine (ASAM) National Practice Guideline for the use of medications in the treatment of addiction involving opioid use","volume":"9","author":"Kampman","year":"2015","journal-title":"Journal of Addiction Medicine"},{"key":"10.1016\/j.jsat.2021.108686_bb0055","series-title":"Survival analysis: Techniques for censored and truncated data","author":"Klein","year":"2003"},{"key":"10.1016\/j.jsat.2021.108686_bb9020","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.drugalcdep.2017.06.009","article-title":"Racial and ethnic differences in opioid agonist treatment for opioid use disorder in a U.S. national sample","volume":"178","author":"Krawczyk","year":"2017","journal-title":"Drug and Alcohol Dependence"},{"issue":"9","key":"10.1016\/j.jsat.2021.108686_bb9030","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1001\/jamapsychiatry.2019.0876","article-title":"Buprenorphine Treatment Divide by Race\/Ethnicity and Payment","volume":"76","author":"Lagisetty","year":"2019","journal-title":"JAMA Psychiatry"},{"issue":"10","key":"10.1016\/j.jsat.2021.108686_bb0060","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1111\/add.12266","article-title":"Comparison of behavioral treatment conditions in buprenorphine maintenance","volume":"108","author":"Ling","year":"2013","journal-title":"Addiction"},{"key":"10.1016\/j.jsat.2021.108686_bb0065","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jsat.2018.11.002","article-title":"A retrospective analysis of treatment and retention outcomes of pregnant and\/or parenting women with opioid use disorder","volume":"97","author":"Lopian","year":"2019","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"12","key":"10.1016\/j.jsat.2021.108686_bb0070","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1038\/s41380-018-0094-5","article-title":"Effects of medication-assisted treatment on mortality among opioids users: A systematic review and meta-analysis","volume":"24","author":"Ma","year":"2019","journal-title":"Molecular Psychiatry"},{"issue":"7","key":"10.1016\/j.jsat.2021.108686_bb0075","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1176\/appi.ps.201700363","article-title":"Three-year retention in buprenorphine treatment for opioid use disorder among privately insured adults","volume":"69","author":"Manhapra","year":"2018","journal-title":"Psychiatric Services"},{"key":"10.1016\/j.jsat.2021.108686_bb0080","article-title":"Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence","volume":"2","author":"Mattick","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1016\/j.jsat.2021.108686_bb0085","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.jsat.2017.07.001","article-title":"Injectable naltrexone, oral naltrexone, and buprenorphine utilization and discontinuation among individuals treated for opioid use disorder in a United States commercially insured population","volume":"85","author":"Morgan","year":"2018","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.jsat.2021.108686_bb0090","series-title":"Nasadad releases overview of buprenorphine patient limits","year":"2019"},{"issue":"4","key":"10.1016\/j.jsat.2021.108686_bb0095","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1080\/00952990600918973","article-title":"Behavioral therapy to augment oral naltrexone for opioid dependence: A ceiling on effectiveness?","volume":"32","author":"Nunes","year":"2006","journal-title":"The American Journal of Drug and Alcohol Abuse"},{"issue":"7","key":"10.1016\/j.jsat.2021.108686_bb0105","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1097\/MLR.0000000000000727","article-title":"Patterns of buprenorphine-naloxone treatment for opioid use disorder in a multistate population","volume":"55","author":"Saloner","year":"2017","journal-title":"Medical Care"},{"key":"10.1016\/j.jsat.2021.108686_bb0110","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jsat.2018.09.001","article-title":"Risk factors for discontinuation of buprenorphine treatment for opioid use disorders in a multi-state sample of medicaid enrollees","volume":"95","author":"Samples","year":"2018","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"5152","key":"10.1016\/j.jsat.2021.108686_bb0115","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.15585\/mmwr.mm675152e1","article-title":"Drug and opioid-involved overdose deaths - United States, 2013\u20132017","volume":"67","author":"Scholl","year":"2018","journal-title":"MMWR. Morbidity and Mortality Weekly Report"},{"issue":"5","key":"10.1016\/j.jsat.2021.108686_bb0120","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1177\/1060028017751913","article-title":"Treatment persistence among insured patients newly starting Buprenorphine\/Naloxone for opioid use disorder","volume":"52","author":"Shcherbakova","year":"2018","journal-title":"The Annals of Pharmacotherapy"},{"key":"10.1016\/j.jsat.2021.108686_bb0125","article-title":"Mortality risk during and after opioid substitution treatment: Systematic review and meta-analysis of cohort studies","volume":"357","author":"Sordo","year":"2017","journal-title":"Bmj-British Medical Journal"},{"key":"10.1016\/j.jsat.2021.108686_bb0130","series-title":"2019","author":"Substance Abuse and Mental Health Services Administration","year":"2019"},{"issue":"2","key":"10.1016\/j.jsat.2021.108686_bb0135","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1001\/jama.2021.7374","article-title":"Use of medications for treatment of opioid use disorder among US medicaid enrollees in 11 states, 2014\u20132018","volume":"326","year":"2021","journal-title":"The Journal of the American Medical Association"},{"issue":"3","key":"10.1016\/j.jsat.2021.108686_bb0140","first-page":"1","article-title":"Using time dependent covariates and time dependent coefficients in the cox model","volume":"2","author":"Therneau","year":"2019","journal-title":"Survival Vignettes"},{"issue":"2","key":"10.1016\/j.jsat.2021.108686_bb0145","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.20622","article-title":"Comparative effectiveness of different treatment pathways for opioid use disorder","volume":"3","author":"Wakeman","year":"2020","journal-title":"JAMA Network Open"},{"issue":"5","key":"10.1016\/j.jsat.2021.108686_bb0150","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1002\/cpt.1210","article-title":"Using real-world data to extrapolate evidence from randomized controlled trials","volume":"105","author":"Wang","year":"2019","journal-title":"Clinical Pharmacology & Therapeutics"},{"key":"10.1016\/j.jsat.2021.108686_bb0155","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.drugalcdep.2015.02.030","article-title":"Long-term outcomes from the National Drug Abuse Treatment Clinical Trials Network Prescription Opioid Addiction Treatment Study","volume":"150","author":"Weiss","year":"2015","journal-title":"Drug and Alcohol Dependence"},{"issue":"2","key":"10.1016\/j.jsat.2021.108686_bb0160","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1176\/appi.ajp.2019.19060612","article-title":"Acute care, prescription opioid use, and overdose following discontinuation of long-term buprenorphine treatment for opioid use disorder","volume":"177","author":"Williams","year":"2020","journal-title":"The American Journal of Psychiatry"}],"container-title":["Journal of Substance Abuse Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0740547221004128?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0740547221004128?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T19:56:10Z","timestamp":1760039770000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0740547221004128"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":34,"alternative-id":["S0740547221004128"],"URL":"https:\/\/doi.org\/10.1016\/j.jsat.2021.108686","relation":{},"ISSN":["0740-5472"],"issn-type":[{"value":"0740-5472","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Examining differences in retention on medication for opioid use disorder: An analysis of Ohio Medicaid data","name":"articletitle","label":"Article Title"},{"value":"Journal of Substance Abuse Treatment","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jsat.2021.108686","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108686"}}